Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
The global supply of COVID-19 vaccines has been limited, and concerns have arisen about vaccine supply chain disruptions in developing countries. Heterologous prime-boost vaccination, which involves using different vaccines for the first and second doses, has been proposed to enhance the immune resp...
Main Authors: | Kriangkrai Tawinprai, Pawornrath Jungsomsri, Onnicha Pinijnai, Fahsiri Tavonvunchai, Anchisa Lievjaroen, Paphada Suwannaroj, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Gaidganok Sornsamdang, Teerapat Ungtrakul |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-01-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2023.2206360 |
Similar Items
-
Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
by: Kriangkrai Tawinprai, et al.
Published: (2022-05-01) -
Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
by: Guy Cohen, et al.
Published: (2022-11-01) -
Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
by: Kriangkrai Tawinprai, et al.
Published: (2022-01-01) -
Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand
by: Saraiorn Thonginnetra, et al.
Published: (2022-10-01) -
Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2
by: Enikő Szabó, et al.
Published: (2023-07-01)